YellowLegalPad Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YellowLegalPad

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: John McCarthy	1/5/2010 12:01:04 AM
	of 1182

On the runway are: Alimera Sciences: developing products that treat retina-related diseases.. Anthera Pharmaceuticals is focused on inflammatory diseases and has one drug ready for phase III clinical trials. Aldagen: develops regenerative cell therapies. AVEO Pharmaceuticals: developing cancer drugs. Codexis: develops enzymes and microbes that make industrial processes cleaner and faster. Ironwood Pharmaceuticals whose first in class compound, is being evaluated in a confirmatory Phase III program for the treatment of irritable bowel syndrome. Rules Based Medicine: a diagnostics company. Tengion: involved in regenerative medicine. Trius Therapeutics: focuses on the development of antibiotics for serious infections. in.sys-con.com • A number of health care IPOs were filed over the weekend, including a $90 million filing from Rules-Based Medicine (NASDAQ:RULE), a $80 million IPO from Alimera Sciences (NASDAQ:ALIM). Dehaier Medical Systems (NASDAQ:DHRM) expects its IPO to be price at $7-$9. zacks.com CRACKER

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next